In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Blockcluster Model: An Alternate Path To Profitability

Executive Summary

As blockbuster pipelines dwindle, some large manufacturers see building portfolios of drugs for narrow, related clusters of indications as significant market opportunities. Companies such as GSK, Genzyme, Novartis and Pfizer are finding success with assets that truly address an unmet need and have the potential to be reimbursed at a premium price. However, in many cases, the development and commercialization of narrow-indication drugs are not easy tasks.

Advertisement

Related Content

Xalkori And The Art Of Modern Drug Development
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel